8-K current report · filed Nov 6, 2026

PULSE BIOSCIENCES, INC. (PLSE) 8-K Current Report: November 6, 2026

Item 8.01Item EX-99.1PLSE overview

Short answer

PULSE BIOSCIENCES, INC. (PLSE) filed an 8-K current report with the SEC on November 6, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Interim six-month data from 43 patients in PRECISE-BTN supports nPulse Vybrance for symptomatic benign thyroid nodules.

PULSE BIOSCIENCES, INC. 8-K event analysis

AI summary of each reported item and its exhibits

Item 8.01 · Other Events

  • Interim six-month data from 43 patients in PRECISE-BTN supports nPulse Vybrance for symptomatic benign thyroid nodules
  • 86% achieved the primary endpoint, at least 50% nodule-volume reduction
  • Median nodule-volume reduction reached 72%, with most reduction by one month
  • Quality-of-life impact improved 78%, while 82% reported complete resolution of neck pressure or fullness
  • No serious adverse events reported, strengthening the device’s safety and commercialization case

Item EX-99.1 · Exhibit EX-99.1

  • Interim six-month PRECISE-BTN results support clinical efficacy: 86% of 43 evaluated patients achieved at least 50% nodule reduction
  • Median nodule volume reduction reached 72%, with improvement beginning by one month after a single treatment
  • Quality-of-life impact improved 78%, while neck pressure or fullness resolved in 82% of affected patients
  • No serious adverse events reported, supporting nsPFA’s potential safety advantage over thermal or surgical alternatives
  • Full 100-patient six-month results and 12-month follow-up remain key catalysts for validation and regulatory progress

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other PULSE BIOSCIENCES, INC. 8-K filings

Get the next PLSE 8-K as it lands

Follow PLSE for push alerts, or ask the research agent what this filing means.